溶瘤病毒
卵巢癌
医学
肿瘤科
化疗
内科学
临床试验
妇科癌症
卡铂
妇科肿瘤学
癌症
顺铂
作者
John P. Micha,Mark A. Rettenmaier,Peter D Giuliano,Randy Bohart,Bram H. Goldstein
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2022-03-23
卷期号:33 (5): 513-516
被引量:2
标识
DOI:10.1097/cad.0000000000001296
摘要
Platinum-resistant ovarian cancer frequently develops in response to multiple lines of chemotherapy, whereupon the disease becomes relatively intractable and clinical recourse is limited. We document a 58-year-old, advanced-stage, platinum-resistant ovarian cancer patient who previously failed numerous cytotoxic and targeted therapy regimens. She was referred to our gynecologic oncology service with a California (CA)-125 of 3194 U/mL and underwent a modified vaccinia virus coinciding with an Institutional Review Board-approved clinical trial. Following the oncolytic therapy and cycle 8 chemotherapy, the patient's CA-125 declined to 440 U/mL; a computerized tomography scan of the abdomen and pelvis revealed a partial response to therapy. The favorable clinical benefit encountered in our case study indicates that the combination of oncolytic viral therapy and chemotherapy should be considered as a therapeutic option for heavily pretreated ovarian patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI